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The COVID-19 pandemic: impact on NHS England PET-CT 
services and lessons learnt
Wai Lup Wonga, Peter Rossb, Kevin Petersc, Marion Frenzd, Tong Haie, 
Alex Ridgeonf, Ralph Toopg, Peter Strouhalh and Jamshed Bomanji        
Purpose The purpose of the study was to examine the 
impact of the first wave of COVID-19 on National Health 
Service (NHS) 18F-fluorodeoxyglucose positron emission 
tomography computed tomography (FDG PET-CT) 
scanning activity across England.
Methods Monthly FDG PET-CT scanning activity was 
collected from 41/48 NHS England provider sites. Data 
from 31/41 sites were stratified by nononcology/oncology, 
cancer type, with lung cancer and lymphoma split into 
specific indications, turn-around times and delays due to 
radiotracer.
Results In April and May 2020, a 32 and 31% decrease 
in activity was observed, a larger decrease for noncancer 
compared with cancer FDG PET-CT. In June 2020, 
activity started to recover with 6% fewer scans recorded 
compared with June 2019. Of the six most common 
indications, lung and oesophageal cancer had the largest 
decrease in activity and slowest recovery. Lymphoma and 
melanoma showed the smallest decrease and fastest 
recovery. Lung cancer scans for initial diagnosis/staging 
saw the largest fall and slowest recovery compared with 
scans for known lung cancer. There was no percentage 
increase in overall turn-around time compared with the 
same months in 2019, and no increase in turn-around time 
of more than 7 working days due to FDG supply during 
April and May 2020 compared with the 3 previous months.
Conclusions There is no correlation between FDG 
PET-CT activity (fall and recovery) in England and the 
ability to provide the service by NHS England. It most 
likely reflects a combination of changes in health-seeking 
behaviour, NHS health policy and a decrease in the 
use of investigations that carry a high risk of COVID-19 
transmission. Nucl Med Commun XXX: 000–000 Copyright 
© 2020 The Author(s). Published by Wolters Kluwer 
Health, Inc.
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Introduction
The coronavirus disease (COVID-19) has resulted in 
21 213 649 million confirmed infections and 760 421 
deaths as of 15 August 2020 and the pandemic shows 
little sign of abating [1]. The COVID-19 pandemic has 
had a substantial impact on healthcare systems and that 
includes diagnostic imaging services. A special report 
of the Radiological Society of North America COVID-
19 task force reported a 40–90% decline of examination 
volumes in radiology practices during the COVID-19 
pandemic [2]. Further, a retrospective review of imaging 
volumes from the largest healthcare system in New York 
state reported a 28% reduction in imaging volume during 
the first-wave COVID-19 pandemic [3]. Several surveys 
have evaluated the impact of COVID-19 on nuclear med-
icine services [3–6]. Across the world, all surveys showed 
that COVID-19 had resulted in a significant decline in 
nuclear medicine scanning, with some centres experi-
encing a decrease in activity of up to 85% [6]. However, 
none of these studies were PET-CT focussed and as such 
do not analyze the variation or magnitude of change in 
PET-CT imaging volumes during the period using pres-
ent real-world data.
PET-CT is one of the main diagnostic tests in the inves-
tigation of people with cancer [7,8]. It is also used for the 
assessment of some nononcological disorders, including 
sarcoidosis, vasculitis, infection, orthopaedics and some 
neurological and cardiac conditions [7,8]. National Health 
Service (NHS) England commissions PET-CT ser-
vices across England through a number of NHS Trusts, 
research institutes, charitable trusts and independent 
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sector providers with a total of over 130 000 PET-CT 
scans performed during the calendar year 2019.
Throughout the first wave of the COVID-19 pandemic, 
NHS England PET-CT sites continued to provide ser-
vices. Moving out of the first wave, the priority within 
NHS England, has been to return healthcare services 
to as near as possible to pre-COVID levels. With this 
comes the requirement for diagnostic services, includ-
ing PET-CT, to meet demand while conforming to new 
COVID-19 well-tolerated measures [9,10]. An accurate 
and detailed understanding of the changes in PET-CT 
scanning activity during the first wave, and the ability 
of PET-CT services to recover, can contribute to ensur-
ing that management plans for people with cancer are 
not delayed in the future and that relapse of disease in 
cancer survivors is detected in a timely fashion. This is 
particularly relevant, as at the time of writing, the UK is 
experiencing a sharp rise in incidence of COVID-19 and 
a second wave of the pandemic [11].
The study examined the impact of the first wave of the 
COVID-19 pandemic on 18F-fluorodeoxyglucose posi-
tron emission tomography computed tomography (FDG 
PET-CT) scanning across England. The primary aim of 
the study was to describe the impact of the first wave 
of the pandemic on nononcology and oncology FDG 
PET-CT activity across NHS England sites. The sec-
ondary aim of the study was to assess the ability of NHS 
England PET-CT services to meet demand by evalu-
ating the time taken for booked FDG PET-CT scans 
to be completed and the extent to which FDG supply 
impacted on FDG PET-CT service.
Methodology
NHS England provides healthcare to a population 
of 55.98 million. A retrospective review of the FDG 
PET-CT scanning activity within NHS England was 
undertaken. FDG PET-CT scanning activity data from 
January to June 2019 and January to June 2020 was col-
lected from 41 sites out of a total of 48 NHS England 
provider sites from which data were requested. In total, 
the data collected accounted for more than 90% of all 
FDG PET-CT scanning across NHS England. The data 
provided from each of the sites were aggregated monthly 
data. Within 31 of the 41 sites, the data were further 
stratified according to nononcology and oncology. The 
oncology data included the number of FDG PET-CT 
scans completed for the six most common indications for 
FDG PET-CT in England: lymphoma, melanoma, lung, 
oesophageal, colorectal and head and neck cancer. Lung 
cancer scanning activity was further split between FDG 
PET-CT for initial diagnosis/staging and FDG PET-CT 
for subsequent diagnosis of recurrence, surveillance and 
restaging. Lymphoma FDG PET-CT activity was fur-
ther split between FDG PET-CT for initial staging and 
FDG PET-CT for subsequent management. Analysis of 
the cancer subgroups was restricted to the 31 sites that 
we requested data from. For the 31 sites, the percentage 
of booked FDG PET-CT scans completed in less than 
5 working days, the percentage of booked FDG PET-CT 
scans completed within 7 working days and the per-
centage of FDG PET-CT scans which took more than 
7 working days to complete were evaluated as markers to 
assess the impact of COVID-19 on the ability of PET-CT 
services to meet demand during pandemic. An FDG 
PET-CT scan is completed when a clinical report has 
been made and the report has been sent to the referrer 
of the FDG PET-CT scan. In addition, for the 31 sites, 
the percentage of booked FDG PET-CT scans not com-
pleted within 7 days due to FDG was evaluated.
Statistics
The quantitative data collected were compiled in a data-
base using Excel before being analysed using Stata soft-
ware to assess the distribution and statistical significance 
of the variation in monthly FDG PET-CT scanning activ-
ity. Data variables were generated to facilitate a compar-
ison of the pre-COVID-19 period (January to June 2019) 
and COVID period (January to June 2020). The imaging 
volumes for each month were summed and descriptive 
statistical methods were applied to demonstrate the vari-
ation and trend in imaging activity for both periods. The 
variation in activity during January to June 2020 was then 
compared with the same months in 2019. The percentage 
change values and mean activity volumes for each month 
were calculated and independent t-tests were undertaken 
to assess the statistical significance for P values <0.05.
Results
The data show a decrease in the number of FDG PET-CT 
scans done between January and June 2020 compared 
with the same period in the previous year. The decrease 
was mainly due to a lower volume of FDG PET-CT scan-
ning activity between April 2020 and May 2020 (Fig. 1). A 
total of 50 879 FDG PET-CTs were completed between 
January 2020 and June 2020, compared with 52 460 FDG 
PET-CTs completed for the same period in 2019. Overall, 
there was a −32% fall in total volume of FDG PET-CTs 
performed in April 2020 compared with April 2019 and 
a fall of −31% in May 2020 compared with May 2019 
(Table 1, Fig. 2).
In June 2020, FDG PET-CT scanning activity returned 
to a level of activity that was closer to that of the previous 
year with an overall percentage decrease of −6% com-
pared with June 2019 (Fig. 2, Table 1). Out of 41 sites in 
June 2020, 16 sites showed a percentage increase in activ-
ity, whereas 25 sites reported a percentage decrease in 
activity compared to June 2019. With respect to range, 20 
sites were within an interquartile range of between −15 
and +6% for percentage change in activity, whereas 10 
sites were below the 25 percentile (marked as red dots in 
Fig. 3) and 11 sites reported a percentage change above 
the 75 percentile (Figs. 3).
On closer inspection of the data, a more pronounced 
decrease in activity was observed in nononcology FDG 
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Fig. 1
Comparison of total volume of PET-CTs completed: January to June for the years 2019 and 2020. 1 – January, 2 – February, 3 – March, 4 – April, 
5 – May, 6 – June.
Table 1 Total monthly PET-CT activity and percentage change year-on-year for January–June 2020
 January February March April May June
2019 total no. Scans 10 421 10 244 10 168 9 927 10 471 10 229
2019 mean 254 250 248 242 255 249
2020 total no. Scans 11 744 10 810 10 672 6 778 7 323 9 652
2020 Mean 286 264 260 165 176 235
P value 0.44 0.73 0.74 0.01* 0.01* 0.69
Change year-on-year (%) 13 6 5 −32 −31 −6
P value reported is based on an independent t-test comparing two means.
* P < 0.05
Fig. 2
Percentage change year-on-year in volume of PET-CTs completed for months January to June 2020. 1 – January, 2 – February, 3 – March, 4 – 
April, 5 – May, 6 – June.
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PET-CT scanning. In 2020, 30 616 oncology scans were 
completed and 1817 nononcology scans were completed 
compared with 31 845 oncology scans and 1852 nonon-
cology scans in 2019. As a percentage, nononcology FDG 
PET-CT scanning decreased by −55 and −33%, respec-
tively, during April and May 2020, compared with a decrease 
of −23 and −26%, respectively, for oncology (Fig. 4).
Within oncology, a dip in FDG PET-CT scanning activ-
ity over April and May 2020 was associated with the type 
of cancer investigated. In April 2020, the percentage 
decrease was most marked for oesophageal cancer, fol-
lowed by lung cancer, head and neck cancer, colorec-
tal cancer and melanoma, with lymphoma showing the 
smallest dip. A similar trend was observed in May 2020 for 
oesophageal cancer, lung cancer, colorectal cancer, head 
and neck cancer and lymphoma. Melanoma, however, 
did not show this trend; instead it showed an increase in 
activity above that of June 2019 (Fig. 5, Table 3).
In June 2020, FDG PET-CT scanning activity related 
to melanoma and lymphoma returned to their previous 
Fig. 3
Percentage change in PET-CT activity at site level: year-on-year for the month June 2020.
Fig. 4
Percentage change in volume of oncology and nononcology PET-CTs completed: year-on-year for the months January–June 2020. 1 – January, 2 
– February, 3 – March, 4 – April, 5 – May, 6 – June.
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year’s performance. In addition, scanning activity in 
colorectal and head and neck cancer returned near to 
their previous year’s performance at −3 and −5%, respec-
tively. In contrast, lung and oesophageal cancer reported 
a −23 and −26% decrease in activity compared with the 
previous year (Fig. 5, Table 3). With regard to lung can-
cer, the level of scanning activity at all 31 sites remained 
below that of the previous year. At an individual site 
level, the median level of activity for lung cancer in June 
2020 was −26% with an interquartile range of between 
−33 and −10% (Fig. 6).
Comparing lymphoma and lung cancer FDG PET-CT 
scanning activity, scans related to the diagnosis and stag-
ing of lung cancer saw a fall in activity of −29% in April 
2020, −47% in May 2020 and −26 % in June 2020 com-
pared with −9% in April 2020, −28% in May 2020 and −14 
% in June 2020 for lymphoma. FDG PET-CT scanning 
related to the care of people with lymphoma following 
their diagnosis showed a fall in activity of −17% in April 
2020, +5% in May 2020 and +31% in June 2020 compared 
with −29% in April 2020, −19% in May 2020 and +2% in 
June 2020 for PET-CTs for the care of people with lung 
cancer following their diagnosis (Fig. 7).
An analysis of the ability of the PET-CT service to meet 
demand showed that the percentage of FDG PET-CT 
scans that had a turn-around time of more than 7 work-
ing days during April and May 2020 was lower compared 
with the same months in 2019. Further, there was an 
increase in the percentage of FDG PET-CT scans that 
had a turn-around time of less than 5 days during April 
and May 2020 during the same period in 2019 (Fig. 8a,b). 
In addition, the data showed that there was no increase 
in turn-around time of more than 7 working days due to 
FDG supply during April and May 2020 compared with 
the January, February and March 2020 (Table 4).
Discussion
The study gives rise to several key findings [1]. Our 
data show that FDG PET-CT scanning in England fell 
significantly during the first wave of the COVID-19 
pandemic [2]. However, FDG PET-CT oncology activ-
ity was less affected when compared with nononcology 
FDG PET-CT [3]. The pace of recovery post COVID-
19 shows that by June 2020 most sites had returned to 
the previous years’ level of activity with the percentage 
change in nononcology activity 6% higher than 2019 and 
oncology −4% lower.
Drawing from the diagnostic imaging databases, a sim-
ilar trend of decrease and recovery to FDG PET-CT 
was seen in the magnetic resonance, CT and ultrasound 
activity over the first wave of the pandemic. However, 
the decrease in activity for these imaging modalities 
was more severe compared with FDG PET-CT. In 
Fig. 5
Percentage change year-on-year for the months January–June 2020 in global FDG PET-CT scanning activity related to indications for PET-CT. 1 
– January, 2 – February, 3 – March, 4 – April, 5 – May, 6 – June. FDG PET-CT, 18F-fluorodeoxyglucose positron emission tomography computed 
tomography.
Table 2 Total percentage change (year-on-year over the period 
January–June 2020) in the number of PET-CT scans completed 
across six cancers
Total number of PET-CT 
scans done 2019 2020 Change (%): 2019/20
Lung cancer 10 606 9399 −11
Oesophageal cancer 1816 1367 −25
Melanoma 1294 1465 13
Head and neck cancer 2525 2452 −3
Colorectal cancer 2376 2332 −2
Lymphoma 6907 6850 −1
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Fig. 6
Monthly percentage change (year-on-year for the months January–June 2020) in PET-CT lung cancer activity across 31 NHS England sites. NHS, 
National Health Service; PET CT, positron emission tomography computed tomography.
Fig. 7
Monthly percentage change (year-on-year for the months January–June 2020) in PET CT related to specific indications for lung cancer and lym-
phoma.1 – January, 2 – February, 3 – March, 4 – April, 5 – May, 6 – June.
Table 3 Monthly percentage change (year-on-year for months January–June 2020) in the number of PET-CT scans completed across six 
cancers
Cancer January February March April May June
Lung 15 1 16 −29 −45 −23
Oesophagus −9 −17 9 −43 −59 −26
Melanoma 41 16 24 −16 5 14
Head and neck 29 −3 4 −20 −22 −5
Colorectal 17 4 9 −18 −23 −3
Lymphoma 2 −6 10 −14 −9 12
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Impact of COVID-19 on NHS England PET-CT services Wong et al. 7
addition, the recovery of FDG PET-CT activity was 
more rapid compared with the other modalities (Fig. 8, 
Table 5).
The extent of the decrease in FDG PET-CT scanning 
activity corroborates the findings from a British Nuclear 
Medicine Society (BNMS) survey completed by 138 
members between 23 March and mid May 2020. The 
BNMS members’ survey findings reported an average 
reduction in PET-CT scanning activity of 32%, which 
exactly matched the activity data from our study [12]. 
Further, our results also support the findings of a web-
based survey by Freudenberg et al. which surveyed 434 
respondents from 72 countries between 16 April 2020 
and 3 May 2020. Their study found an average decline in 
PET-CT services of 36% [4]. In our study, the decrease 
in scanning activity coincided with the peak of incidence 
of COVID-19 in England and the period of national lock 
down [12]. The decline was most marked between April 
and May 2020 when a decrease of 32 and 31%, respec-
tively, was observed when compared to the same months 
in the previous year.
Our study’s findings indicate that the fall in activity was 
not associated with any inability to deliver PET-CT 
services. There was no increase in turnaround times for 
people booked for FDG PET-CT scanning during April 
and May 2020, the period which saw the biggest fall in 
FDG PET-CT scanning activity. Instead, the percentage 
of booked scans completed which took more than 7 work-
ing days was lower in April and May compared to the 
same period during the previous year. Furthermore, the 
Fig. 8
(a) Monthly percentage of FDG PET-CT scans turned around in more than 7 working days. (b) Monthly percentage of FDG PET-CT scans turned 
around in less than 5 working days. FDG PET-CT, 18F-fluorodeoxyglucose positron emission tomography computed tomography.
Table 4 Percentage of scans with turn-around time >7 working 
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percentage of booked FDG PET-CT scans completed 
in less than 5 working days increased. There was also 
no increase in turn-around time of FDG PET-CT scans 
because of FDG supply problems during April and May 
2020. Instead, there was a decrease in the percentage of 
FDG PET-CTs delayed because of FDG supply.
Our study suggests that factors beyond the control of 
FDG PET-CT sites were responsible for the decrease 
in FDG PET-CT activity. First, prioritisation of service 
was a major factor. Prioritisation of people with COVID-
19 and cancer services in preference to nononcology 
services during the first wave had a major impact on 
scanning activity. European guidance published at the 
time advised on the importance of prioritising essential 
nuclear medicine procedures over nonessential proce-
dures if possible [10,13,14]. In the UK, the BNMS rec-
ommended prioritising PET-CT for people with new 
cancers and sepsis over other PET-CTs if possible [15]. 
Our data showed that the decrease in nononcology FDG 
PET-CT activity was much higher compared with the 
decrease in cancer scanning activity. This observation is 
concordant with four other studies which showed that 
during the COVID-19 pandemic, noncancer nuclear 
medicine scan activity was more affected when compared 
with cancer nuclear medicine scans [4,16,17]. Specifically, 
a study by Freudenberg et al. found that while PET-CT 
cancer scanning activity decreased by an average of 36%, 
the number of thyroid studies fell by 67%, myocardial 
studies 66%, bone scans 60%, lung scans 65% and sen-
tinel node procedures by 45% [4]. Second, a web-based 
survey carried out by Fruedenberg et al. over 6 days in 
April 2020 with respondents from Germany, Austria and 
Switzerland, reported a decline in PET-CT of -14.4% 
compared with a decline in myocardial perfusion imaging 
of −47.2% and radiosynoviothesis of −58.4% [16]. Third, 
the survey of BNMS members reported that the decline 
in PET-CT was less pronounced than that compared 
with other nuclear medicine investigations. It reported 
that ‘the most affected area of nuclear medicine in con-
ventional diagnostic nuclear medicine was thyroid, para-
thyroid and renal imaging, they were all reduced by more 
than 75%. Oncology PET-CT and some therapies such 
as selective internal radiation therapy and Ra-233 were 
the least effected’ [12]. Finally, in an Italian single centre 
study in which 94% of PET-CT scans were conducted for 
cancer, no statistically significant difference was found in 
the number of PET-CTs done between February and 
April 2020 compared with the same period in 2019 [17].
A further factor that contributed to the decrease in FDG 
PET-CT activity was changes in decision making within 
multidisciplinary team (MDT) meetings. Some col-
leagues and MDTs coped with COVID-19 by bypassing 
or delaying PET-CT scans for initial staging and for one 
of the response assessment scans1: ‘when I am told we 
have a theatre slot available at the end of the week, I 
go ahead with surgery and bypass the planned PET-CT, 
especially when I think it is probably unlikely that the 
person has distant metastases’. There was also in some 
centres a reduction in the use of surveillance PET-CT 
scanning: ‘if a person is well, and for whatever reason 
missed a planned follow-up PET-CT, we will just wait till 
the next time the person is due for a scan to do the scan’.
Service prioritisation and changes in decision making at 
MDTs were not the only factors. Another factor which 
would have added to the decrease in activity was a change 
in health-seeking behaviour, which resulted in a fall in 
Table 5 Total monthly CT, ultrasound (USS), magnetic resonance activity and percentage change year-on-year for January- June 2020.
CT January February March April May June
 2019 total no. of scans 499 632 452 740 494 920 479 215 501 830 487 155
 2020
total no. of scans
534 605 493 035 420 070 269 830 351 185 404 695
 % change +7.0% +8.9% −15.1% −44.0% −30.0% −16.9%
USS       
 2019 total no. of scans 912 130 801 285 864 995 851 880 840 450 840 450
 2020 total no. of scans 913 220 820 455 704 450 357 840 429 605 569 530
 % change 0.12% 2.4% −1.22% −58.0% 48.9% −32.2%
MRI       
 2019 total no. of scans 324 475 296 565 323 100 308 065 315 900 315 900
 2020 total no. of scans 333 005 314 410 270 555 99 225 140 795 202 330
 % change +2.6% +6.0% −16.3% −32.1% −55.4% −35.9%
Source: Diagnostic imaging dataset https://www.england.nhs.uk/statistics/statistical-work-areas/diagnostic-imaging-dataset/ accessed 11 November 2020
Table 6 Lessons learnt from the first wave of the COVID-19 
pandemic
Lessons learnt
(1) During the first wave of the pandemic, NHS England PET-CT sites 
continued to maintain robust FDG PET-CT services. The decrease in 
FDG PET-CT activity was due to demand side factors beyond the direct 
control of NHS PET-CT services.
(2) Changes in service prioritisation, the decision making at MDTs and 
changes in health-seeking behaviour, contributed to a fall in FDG PET-CT 
scanning activity. The suspension or operation under reduced capacity of 
endoscopy and bronchoscopy services also contributed to the fall.
(3) In future, a better understanding of the impact of COVID-19 on clinical 
pathways will be key to ensuring that PET-CT services are adapted to 
meet the changing pattern of demand.
NHS, National Health Service.
1This was a contributory factor identified on interview with MDT leads at the 
Mount Vernon Cancer centre.
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the number of people going to their general practitioner 
(GP) with signs and symptoms of cancer and as a result 
the number of suspected cancer referrals to hospital 
[18,19]. By contrast to nononcology FDG PET-CT, there 
was a clear message from professional organisations that 
PET-CT services for people with cancer should as far as 
possible remain uninterrupted, and this was reflected in 
published guidance [14]. Nevertheless, there was a fall in 
activity in cancer FDG PET-CT, all be it not as great as 
nononcology FDG PET-CT.
However, these factors do not account fully for the differ-
ence observed in activity between the tumor types. Lung 
cancer showed a statistically significant larger fall in activ-
ity and also a significantly slower recovery compared to 
lymphoma. The suspension or operation under reduced 
capacity of essential diagnostic services, including endos-
copy and bronchoscopy, likely contributed significantly 
to this. The number of endoscopies done in April 2020 
was 90% fewer than that performed in the first three 
months of 2020 [20]. Bronchoscopy and endoscopy are 
aerosol-generating procedures that carry a risk of severe 
acute respiratory syndrome coronavirus 2 transmission; 
risk mitigation strategies mean that the number of colo-
noscopies bronchoscopies that can be done per day had 
to be much lower than before the pandemic.
With regard the to the overall recovery of FDG PET-CT 
services, the data from this study demonstrated that by 
June 2020, most sites had returned to their previous 
year’s level of activity with the percentage change in 
nononcology activity 6% higher than 2019 and oncol-
ogy −4% lower. However, as with decline in activity, the 
extent of the recovery was not uniform across the cancer 
types. FDG PET-CT scanning in lung cancer showed a 
slower recovery compared with scanning for lymphoma. 
This further supports the impact of decreased bronchos-
copy and endoscopy on FDG PET-CT activity. As of 
June 2020, these diagnostic services had restarted but at 
reduced capacity [21].
With regard to the pace of recovery, data from 31 sites 
show that the pace of recovery since June 2020 has been 
variable across sites. Comparing June 2020 with the same 
month in the previous year, scanning activity for the best 
performing sites improved by up to +65% compared with 
−34% for the lowest performing site. By August 2020, the 
gap in scanning activity between sites had widened with 
scanning activity improving by as much as +650% in the 
best performing site compared with up to −1% for the 
slowest sites. The difference highlights the variation in 
pace of regional recovery. Contributing to this divergence 
is the ability of bronchoscopy and endoscopy services 
to recover. There is also an increasing awareness of the 
regional differences in health-seeking behaviour of peo-
ple during COVID-19, magnified by social inequalities 
[18–24].
Three caveats need to be considered when evaluating 
the extent of the recovery in PET-CT activity during 
the first wave of the pandemic. First, the activity data 
do not take account of any increase in the trend rate of 
growth in FDG PET-CT activity, which pre-COVID-19 
was growing at a rate of somewhere between 5 and 15% 
per annum. Second, a possible backlog of FDG PET-
CTs has not been taken into account when considering 
Fig. 9
Comparison of percentage change in total volume of PET-CTs, CT, MRI and ultrasound (USS) completed: January to June for the years 2019 and 
2020.
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the recovery in activity in June 2020. According to 
Cancer Research UK at the start of June 2020, there 
was an estimated 2.4 million people in the backlog for 
screening, tests or treatment. Further, NHS England 
data from 11 June 2020 show that the number of urgent 
GP referrals for cancer dropped by 60% in April com-
pared with the same month in the previous year, and 
the number of people starting treatment following an 
urgent GP referral declined by 18% [17]. The third 
caveat concerns the fact that the activity data for June 
2020 do not factor in the alternative treatment plans 
that may have been adopted by clinicians during the 
peak of the pandemic so as to circumvent the need for 
a PET-CT scan. In line with national and local guid-
ance, nonsurgical treatment was considered in favour of 
surgery. Systemic treatment and radiotherapy regimens 
were changed and modified all in an effort to reduce 
the risk of spread of COVID-19 infection and to con-
serve healthcare resources for COVID-19 patients [18]. 
In short, the above considerations need to be taken 
in consideration when an attempt is made to predict 
future PET-CT demand.
Some of the observations and lessons learnt from this 
study can be useful for assisting with planning services 
for the current second wave and possible subsequent 
waves. First, it highlights that the demand for PET CT 
is very much dependent on the changes that occur in the 
clinical pathway upstream. A detailed appreciation of the 
impact of COVID-19 on clinical pathways, which include 
PET-CT, will be key to ensuring that PET-CT services 
are organised to meet demand. In addition, given the rel-
ative robustness of PET-CT, during the first wave, com-
missioners and clinicians should perhaps place PET-CT 
earlier in the diagnostic pathway during the second and 
in subsequent waves. Adopting this approach would 
result in fewer imaging episodes, thus making it safer 
for patients and staff. In addition, it will improve patient 
experience and free up other scanning for other use. For 
example, with respect to people with lung cancer and a 
relatively high risk of distant metastases, it may be rea-
sonable to consider FDG PET-CT as the initial staging 
investigation (Table 6).
Conclusion
Drawing on activity data from 41 sites across NHS 
England, this study demonstrated a significant fall of up 
to 32% in FDG PET-CT scanning activity during the 
first wave of the COVID-19 pandemic. There is no corre-
lation between FDG PET-CT activity (fall and recovery) 
in England and the ability of NHS England to provide 
FDG PET-CT services. It most likely reflects a combina-
tion of changes in health-seeking behaviour, NHS health 
policy and a decrease in the use of investigations that 
carry a high risk of COVID-19 transmission, specifically 
endoscopy and bronchoscopy.
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